Literature DB >> 15893432

Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.

D Centonze1, P Gubellini, S Rossi, B Picconi, A Pisani, G Bernardi, P Calabresi, C Baunez.   

Abstract

Subthalamic nucleus (STN) is a target of choice for the neurosurgical treatment of Parkinson's disease (PD). The therapeutic effect of STN lesion in PD is classically ascribed to the rescue of physiological activity in the output structures of the basal ganglia, and little is known about the possible involvement of the striatum. In the present study, therefore, we electrophysiologically recorded in vitro single striatal neurons of DA-depleted rats unilaterally lesioned by 6-hydroxydopamine, treated or not with therapeutic doses of levodopa (l-DOPA), or with a consecutive ipsilateral STN lesion. We show that the beneficial motor effects produced in parkinsonian rats by STN lesion or l-DOPA therapy were paralleled by the normalization of overactive frequency and amplitude of striatal glutamate-mediated spontaneous excitatory postsynaptic currents (sEPSCs). Since neither l-DOPA treatment nor STN lesion affected sEPSCs kinetic properties, the reversal of these abnormalities in striatal excitatory synaptic transmission can be attributable to the normalization of glutamate release.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893432     DOI: 10.1016/j.neuroscience.2005.03.006

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  16 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

2.  Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.

Authors:  Shen Yin; Meredith J Noetzel; Kari A Johnson; Rocio Zamorano; Nidhi Jalan-Sakrikar; Karen J Gregory; P Jeffrey Conn; Colleen M Niswender
Journal:  J Neurosci       Date:  2014-01-01       Impact factor: 6.167

Review 3.  Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?

Authors:  Paolo Calabresi; Veronica Ghiglieri; Petra Mazzocchetti; Ilenia Corbelli; Barbara Picconi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

4.  Subthalamic lesion or levodopa treatment rescues giant GABAergic currents of PINK1-deficient striatum.

Authors:  Nathalie Dehorter; Natalia Lozovaya; B Julius Mdzomba; François J Michel; Catherine Lopez; Vera Tsintsadze; Timur Tsintsadze; Michael Klinkenberg; Suzanna Gispert; Georg Auburger; Constance Hammond
Journal:  J Neurosci       Date:  2012-12-12       Impact factor: 6.167

Review 5.  Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

Authors:  Shen Yin; Colleen M Niswender
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

Review 6.  Dysregulation of striatal projection neurons in Parkinson's disease.

Authors:  Goichi Beck; Arun Singh; Stella M Papa
Journal:  J Neural Transm (Vienna)       Date:  2017-06-15       Impact factor: 3.575

Review 7.  Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.

Authors:  Barbara Picconi; Elvira De Leonibus; Paolo Calabresi
Journal:  J Neural Transm (Vienna)       Date:  2018-02-28       Impact factor: 3.575

8.  An examination of the effects of subthalamic nucleus inhibition or μ-opioid receptor stimulation on food-directed motivation in the non-deprived rat.

Authors:  Wayne E Pratt; Eugene Choi; Elizabeth G Guy
Journal:  Behav Brain Res       Date:  2012-02-25       Impact factor: 3.332

Review 9.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

10.  PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking.

Authors:  Gregory Porras; Amandine Berthet; Benjamin Dehay; Qin Li; Laurent Ladepeche; Elisabeth Normand; Sandra Dovero; Audrey Martinez; Evelyne Doudnikoff; Marie-Laure Martin-Négrier; Qin Chuan; Bertrand Bloch; Daniel Choquet; Eric Boué-Grabot; Laurent Groc; Erwan Bezard
Journal:  J Clin Invest       Date:  2012-10-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.